Cushing’s Syndrome Market to Register Sustainable Growth During the Forecast Period (2022-32) | Strongbridge Biopharma, Crinetics, Cyclacel, Sparrow Pharma, AstraZeneca, Corcept Therapeutics

Cushing's Syndrome Market to Register Sustainable Growth During the Forecast Period (2022-32) | Strongbridge Biopharma, Crinetics, Cyclacel, Sparrow Pharma, AstraZeneca, Corcept Therapeutics

“Delveinsight Business Research LLP”
As per DelveInsight, the Cushing’s Syndrome Market is expected to grow in the coming years owing to the rise in the prevalent population of Cushing’s Syndrome in the 7MM. Additionally, the extensive research and development activities of pharmaceutical companies in the therapeutics segment and the expected launch of therapies will also fuel market growth.

DelveInsight’s “Cushing’s Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cushing’s Syndrome Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Cushing’s Syndrome market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Cushing's Syndrome Market

Cushing’s Syndrome: An Overview

Cushing’s Syndrome (CS) is a disorder that occurs when the body makes too much of the hormone cortisol over a long period of time. Cortisol is sometimes called the “stress hormone” because it helps the body respond to stress.

The most common cause of CS is the long-term, high-dose use of cortisol-like glucocorticoids. These medicines are used to treat other medical conditions, such as asthma, rheumatoid arthritis, and lupus. Other people develop endogenous Cushing’s syndrome because their bodies make too much cortisol. Several types of tumors can cause the body to make excess cortisol, such as Pituitary tumors, Ectopic ACTH-producing tumors, and Adrenal tumors.

Treatment of Cushing’s Syndrome depends on the underlying cause of excess cortisol but may perhaps include surgery, radiation, chemotherapy, or the use of cortisol-inhibiting drugs.

Cushing’s Syndrome Market Key Facts

  • According to the Orphanet, the prevalence of endogenous Cushing’s Syndrome (CS) is 1/26,000 and, in the EU, it has an annual prevalence of 1/1,400,000-1/400,000, with a peak prevalence at 25-40 years of age.

  • According to the American Association of Neurological Surgeons, an estimated 10-15 per million people are affected with Cushing’s Syndrome every year.

  • As per the NORD, it is reported that the incidence of endogenous Cushing syndrome is approximately 13 per million people annually.

Cushing’s Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Cushing’s Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Cushing’s Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Cushing’s Syndrome Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Cushing’s Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cushing’s Syndrome market or expected to get launched during the study period. The analysis covers Cushing’s Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cushing’s Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Cushing’s Syndrome Market Will Evolve by 2032 @ https://www.delveinsight.com/sample-request/cushings-syndrome-market

Cushing’s Syndrome Therapeutics Analysis

The Cushing’s Syndrome market dynamics are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, rising awareness of the disease, incremental healthcare spending across the world, and the expected launch of emerging therapies.

Some of the key companies in the Cushing’s Syndrome Therapeutics Market include:

• Strongbridge Biopharma

• Corcept Therapeutics

• Crinetics Pharmaceuticals

• Cyclacel Pharmaceuticals

• Sparrow Pharmaceuticals

• AstraZeneca

And many others

Cushing Syndrome Drugs Covered in the report include: 

• Relacorilant: Corcept Therapeutics

 • SPI-62: Sparrow Pharmaceuticals 

• CRN04894: Crinetics Pharmaceuticals

• Recorlev (levoketoconazole): Strongbridge Biopharma

• AZD4017: AstraZeneca

And many more 

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More-

https://www.delveinsight.com/sample-request/cushings-syndrome-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Cushing’s Syndrome Competitive Intelligence Analysis

4. Cushing’s Syndrome Market Overview at a Glance

5. Cushing’s Syndrome Disease Background and Overview

6. Cushing’s Syndrome Patient Journey

7. Cushing’s Syndrome Epidemiology and Patient Population (In US, EU5, and Japan)

8. Cushing’s Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Cushing’s Syndrome Unmet Needs

10. Key Endpoints of Cushing’s Syndrome Treatment

11. Cushing’s Syndrome Marketed Products

12. Cushing’s Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Cushing’s Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Cushing’s Syndrome Market Outlook (In US, EU5, and Japan)

16. Cushing’s Syndrome Access and Reimbursement Overview

17. KOL Views on the Cushing’s Syndrome Market

18. Cushing’s Syndrome Market Drivers

19. Cushing’s Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/cushings-syndrome-market

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Barlow’s Syndrome Market

“Barlow’s Syndrome Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Barlow’s Syndrome Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/